Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial
暂无分享,去创建一个
F. Cunha | J. Alves-Filho | P. Louzada-Junior | Tamara S. Rodrigues | V. Bollela | F. Vilar | D. Zamboni | C. Del-Ben | T. Cunha | M. Borges | A. Pazin-Filho | C. H. Miranda | M. Auxiliadora-Martins | E. Arruda | L. Leiria | L. Cunha | F. Veras | M. Benatti | R. D. Oliveira | B. Fonseca | R. Santana | A. Schneider | M. Giannini | L. Bonjorno | M. I. Lopes | S. L. Almeida | N. Amaral | U. C. Rezek | Betania A A Sousa | Pamella Indira Da Silva Oliveira Menezes | Saulo Musse Dib | S. Gigante | L. L. Emrich-Filho | Rodrigo Luppino Assad | T. Rodrigues | P. I. Menezes | S. M. Dib | B. A. Sousa | P. Louzada-Júnior | L. D. Cunha | L. O. Leiria
[1] T. Kohlsdorf,et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients , 2020, The Journal of experimental medicine.
[2] Li Tan,et al. Gender, age and comorbidities as the main prognostic factors in patients with COVID-19 pneumonia. , 2020, American journal of translational research.
[3] P. Saldiva,et al. SARS-CoV-2–triggered neutrophil extracellular traps mediate COVID-19 pathology , 2020, The Journal of experimental medicine.
[4] M. Cotelli,et al. Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome , 2020, Annals of the Rheumatic Diseases.
[5] F. Zhou,et al. Clinical Characteristics and Immune Injury Mechanisms in 71 Patients with COVID-19 , 2020, mSphere.
[6] A. Achiron,et al. Cytokine prediction of mortality in COVID19 patients , 2020, Cytokine.
[7] Chunyan Zhu,et al. Obesity aggravates COVID‐19: A systematic review and meta‐analysis , 2020, Journal of medical virology.
[8] Jennifer L. Bell,et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.
[9] A. Tincani,et al. The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al. , 2020, Clinical Rheumatology.
[10] G. Dangas,et al. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019 , 2020, JAMA network open.
[11] Qiurong Ruan,et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China , 2020, Intensive Care Medicine.
[12] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.
[13] Guillermo J. Lagos-Grisales,et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis , 2020, Travel Medicine and Infectious Disease.
[14] Zunyou Wu,et al. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.
[15] Wei Zhao,et al. NLRP3 Inflammasome—A Key Player in Antiviral Responses , 2020, Frontiers in Immunology.
[16] Yan Zhao,et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) , 2020, Military Medical Research.
[17] R. Diaz,et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. , 2019, The New England journal of medicine.
[18] Y. Kihara,et al. Effect of short-term colchicine treatment on endothelial function in patients with coronary artery disease. , 2019, International journal of cardiology.
[19] D. Nassar,et al. Neutrophils contribute to vasculitis by increased release of neutrophil extracellular traps in Behçet's disease. , 2018, Journal of dermatological science.
[20] A. Protogerou,et al. The Role of Colchicine in the Treatment of Autoinflammatory Diseases. , 2018, Current pharmaceutical design.
[21] V. Dixit,et al. Inflammasomes: mechanism of assembly, regulation and signalling , 2016, Nature Reviews Immunology.
[22] A. Iwasaki,et al. Control of adaptive immunity by the innate immune system , 2015, Nature Immunology.
[23] S. Legrand-Poels,et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. , 2014, Diabetes research and clinical practice.
[24] A. Chawla,et al. Macrophage-mediated inflammation in metabolic disease , 2011, Nature Reviews Immunology.
[25] P. Libby,et al. Obesity, inflammation, and atherosclerosis , 2009, Nature Reviews Cardiology.
[26] G. Nuki. Colchicine: Its mechanism of action and efficacy in crystal-induced inflammation , 2008, Current rheumatology reports.
[27] E. Niel,et al. Colchicine today. , 2006, Joint, bone, spine : revue du rhumatisme.